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ABSTRACT
Introduction In Aotearoa New Zealand, Māori and Pacific 
people experience worse health outcomes compared with 
other New Zealanders. No population- based eye health 
survey has been conducted, and eye health services do not 
generate routine monitoring reports, so the extent of eye 
health inequality is unknown. This information is required 
to plan equitable eye health services. Here we outline the 
protocol for a scoping review to report the nature and 
extent of the evidence reporting vision impairment, and the 
use of eye health services by ethnicity in New Zealand.
Methods and analysis An information specialist will 
conduct searches on MEDLINE and Embase, with no limit 
on publication dates or language. We will search the grey 
literature via websites of relevant government and service 
provider agencies. Reference lists of included articles 
will be screened. Observational studies will be included 
if they report the prevalence of vision impairment, or any 
of the main causes (cataract, uncorrected refractive error, 
macular degeneration, glaucoma or diabetic retinopathy) 
or report the use of eye health services in New Zealand 
among people of any age. Two authors will independently 
review titles, abstracts and full- text articles, and complete 
data extraction. Overall findings will be summarised 
using descriptive statistics and thematic analysis, with 
an emphasis on disaggregation by ethnicity where this 
information is available.
Ethics and dissemination Ethical approval has not 
been sought as our review will only include published 
and publicly accessible data. We will publish the review 
in an open access peer- reviewed journal. We anticipate 
the findings will be useful to organisations and providers 
in New Zealand responsible to plan and deliver eye care 
services, as well as stakeholders in other countries with 
differential access to eye care.
Registration details The protocol has been registered 
with Open Science Framework (https:// osf. io/ yw7xb).
INTRODUCTION
Rationale
The recent Lancet Global Health Commission on 
Global Eye Health defined eye health as ‘maxi-
mised vision, ocular health, and functional 
ability, thereby contributing to overall health 
and wellbeing, social inclusion, and quality of 
life’.1 Eye health services are then considered 
any service which contributes to this broad 
definition of eye health. The need for acces-
sible eye health services is large and increasing. 
Globally, an estimated 43 million people were 
blind and 295 million people had moderate 
or severe vision impairment in 2020.2 In high- 
income countries, including Aotearoa New 
Zealand (hereafter referred to as New Zealand), 
the main causes of blindness and moderate or 
severe vision impairment (collectively referred 
to as vision impairment) are cataract, macular 
degeneration, glaucoma, uncorrected refrac-
tive error and diabetic retinopathy.3 Most 
people with vision impairment are older adults, 
however, diabetic retinopathy is the leading 
cause of vision impairment in the working age 
group.4 Diabetic retinopathy is projected to be 
an increasingly common cause of vision impair-
ment in the coming decades due to the rising 
prevalence of diabetes.5
Although some countries are striving to 
reduce health inequalities,6 achieving equitable 
health outcomes is an intractable challenge.7 
In many countries, people who are Indige-
nous, living with socioeconomic disadvantage 
and marginalised communities face barriers to 
accessing healthcare.8 Consequently, systemic 
Strengths and limitations of this study
 ► The broad scope of this review will result in the 
first synthesis to date on the extent of the evidence 
on vision impairment, its main causes and use of 
eye health services across ethnicity groups in New 
Zealand.
 ► The search will be performed by an information 
specialist, and screening and data extraction will be 
performed in duplicate.
 ► We anticipate limited information on some causes of 
vision impairment, and inconsistent disaggregation 
of outcomes by ethnicity.
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and chronic health conditions are more prevalent among 
these people.9 They also tend to have higher rates of vision 
impairment.10 11 For example, in Australia the prevalence of 
cataract is higher among Indigenous people compared with 
non- Indigenous Australians, reflecting lower access to eye 
health services.8 12
Māori, the Indigenous people of New Zealand, are one 
of six main ethnicity groups (defined by Statistics New 
Zealand as ‘a cultural group a person identifies with or 
has a sense of belonging to’).13 In the 2018 census, 70% 
of New Zealanders identified with at least one European 
ethnicity, 17% identified as Māori, 8% identified with 
at least one Pacific peoples’ ethnicity, 15% identified as 
Asian, 2% identified as Middle Eastern/Latin American/
African and 1% identified as other ethnicity.14
Inequities in health and variations between ethnicity 
groups in the prevalence of systemic diseases have been 
reported in New Zealand.15 The health gap is persistent 
between Māori and non- Māori.16 Chronic conditions 
such as diabetes, cardiovascular disease and chronic 
obstructive pulmonary disease are more prevalent among 
Māori compared with other New Zealanders.17 18 Māori 
have a higher need for renal replacement therapy15 and 
a 30% higher risk of developing a cardiovascular event 
compared with European New Zealanders.19 151617 1815
Inequities in eye health are well- documented in several 
high- income countries.12 20 21 In New Zealand, the extent 
of inequity in eye health is largely unknown. New Zealand 
has never had a population- based eye health survey. A 
systematic review has been conducted on diabetic reti-
nopathy prevalence and services,22 but synthesis of infor-
mation on other causes of vision impairment has not 
been undertaken. This information would assist decision- 
makers to plan equitable eye health services.
The aim of this scoping review is to summarise the 
nature and extent of evidence in New Zealand on:
1. The distribution of vision impairment and its major 
causes by ethnicity.
2. Differential access to eye health services by ethnicity.
As there is no New Zealand- specific information avail-
able on the main causes of vision impairment, we will 
assess the evidence on main causes in high- income coun-
tries.3 We chose to undertake a scoping review rather 
than a systematic review, as we anticipate that the avail-
able evidence will be heterogenous.23
METHODS AND ANALYSIS
We will follow the methodological steps for scoping 
reviews outlined by Arksey and O’Malley.23 Our team 
includes researchers (JB, MH, JR) with experience in 
conducting scoping reviews including on service delivery 
models to address inequities in eye health.24 25
Objectives/scoping review questions
To achieve our aim, we will answer the following questions:
1. What is the nature and extent of the available evidence 
on vision impairment in New Zealand?
2. What is the available evidence on the prevalence of the 
major causes of vision impairment in New Zealand?
3. How and in what ways is vision impairment and its ma-
jor causes distributed across ethnicity groups?
4. What is the available evidence on differential access to 
eye health services for the major causes of vision im-
pairment by ethnicity?
Protocol and registration
The protocol for this scoping review is reported according 
to the relevant items of the Preferred Reporting Items for 
Systematic reviews and Meta- Analyses (PRISMA) extension 
for Scoping Reviews checklist (online supplemental annex 
1).26 The protocol has been registered with Open Science 
Framework.
Patient and public involvement
There is no patient or public involvement as our review 
will only include published and publicly accessible data.
Eligibility criteria
We will include studies that meet the following criteria:
Context
Studies will be included if they report outcomes among 
residents of New Zealand (whether disaggregated by 
ethnicity or not), or attendees at New Zealand health 
facilities (regardless of facility size, public/private sector 
or level of care). Multi- country studies will be included if 
the results are reported separately for New Zealand.
Types of studies
Observational study types such as cross- sectional, case–
control and consecutive case series will be included. Non- 
consecutive cases series will be excluded. Research letters 
and grey literature, such as District Health Board (DHB) 
reports will be included, if they report data for at least one 
of our outcomes of interest. Editorials and conference 
abstracts will be excluded. We will have no time limit or 
language restrictions. Only studies where the full article 
is available will be included. We will use the University 
of Auckland’s comprehensive inter- library loan service to 
retrieve articles not readily available.
Participants
We will include studies of any population group resi-
dent in New Zealand. There will be no age or gender 
restriction.
Concept/outcomes
We will include studies that report at least one of:
 ► The prevalence of vision impairment.
 ► The prevalence of cataract, uncorrected refractive 
error, macular degeneration, glaucoma or diabetic 
retinopathy.
 ► The prevalence of vision impairment due to cataract, 
uncorrected refractive error, macular degeneration, 
glaucoma or diabetic retinopathy.
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 ► Attendance at eye health service such as ophthal-
mology services, optometric services and eye health 
screening programmes (eg, diabetic retinal screening, 
children vision screening).
 ► Rates of treatment for cataract, uncorrected refractive 
error, macular degeneration, glaucoma or diabetic 
retinopathy.
We will include studies which report these outcomes by 
person. Studies which only report the outcomes by eye or 
by eye health service visit will be excluded.
Search
Published literature search
We will search MEDLINE and Embase using search strate-
gies developed by a Cochrane Eyes and Vision Information 
Specialist (IG). Our search strategy used on MEDLINE is 
included in online supplemental annex 2. We will apply a 
backward and forward snowball citation approach to iden-
tify potentially relevant studies,27 by examining reference 
lists of all included articles (backward) and examining 
studies which have cited our included articles (forward).
Grey literature search
We will include grey literature that reports data for at 
least one of our outcomes. General search terms will be 
used to identify eligible information within each website. 
Relevant links within documents to other sources of infor-
mation will be pursued. A single reviewer will perform the 
search and identify eligible data, with verification from a 
second reviewer.
Using Google search engine, separate searches will be 
performed across:
 ► New Zealand government websites such as Ministry of 
Health and DHBs.
 ► Professional associations such as New Zealand Associ-
ation of Optometry and the Royal Australian and New 
Zealand College of Ophthalmologists.
 ► Non- profit organisations and charitable trusts such as 
Blind Low Vision New Zealand and Macular Degener-
ation New Zealand.
We will limit our search to the first 20 items of Google 
search engines.
Google search terms will include:
 ► “vision”, “eye”, “eye health”, “eye service”, “vision 
tests” and “vision screening”.
 ► “cataract”, “uncorrected refractive error”, “macular 
degeneration”, “glaucoma” or “diabetic retinopathy”.
In addition, field experts and key stakeholders will 
be contacted to share our list of included studies and 
request they identify further potentially relevant studies 
for consideration in the review.
Study selection
Covidence systematic review software will be used for 
screening (Veritas Health Innovation, Melbourne, 
Australia. Available at: www. covidence. org). Two 
reviewers will independently screen the title and abstract 
of identified studies to exclude publications that clearly 
do not meet the inclusion criteria. The full- text article 
will be retrieved for review (via the University of Auck-
land Library) if the citation seems potentially relevant. 
Any discrepancies between the reviewers will be resolved 
by discussion and a third reviewer will be consulted if 
necessary. A PRISMA flow diagram will be completed to 
summarise the study selection process.
Data charting process
A custom form will be developed in Excel for data 
charting. The form will be piloted on three studies and 
required amendments agreed by consensus. As we antici-
pate a broad scope of studies, the data charting process will 
be iterative and the data charting form will be amended 
as required. Each included study will be charted inde-
pendently by two reviewers. Any discrepancies between 
the reviewers will be resolved by discussion, and a third 
reviewer will be consulted if necessary. We plan to contact 
study authors in the case of unclear information and will 
make up to three attempts by email.
Data items
The following data items will be collected during the data 
charting process:
1. Source characteristics:
a. Published data—author(s), year of publication, ti-
tle, journal and study design.
b. Grey literature—author (organisation, eg, Ministry of 
Health), year of publication, source website (eg, gov-
ernment/non- government organisation), type of liter-
ature (report, thesis, technical report, statistic, other).
2. Study characteristics: year(s) of data collection, sample 
size, age group of study population, demographics of 
study population such as gender and ethnicity. Geograph-
ic area (eg, city, district) and study setting (eg, facility lev-
el).
3. Outcomes as outlined above. We will extract all out-
comes at the aggregate level, as well as disaggregated 
by ethnicity, gender, DHB and area level deprivation 
wherever available.
Synthesis of results
We will summarise findings narratively and in tables. 
Information for each outcome will be disaggregated by 
cause of impairment, ethnicity, age, geographic region 
and area level deprivation where these are available.28
Where possible, we will use Statistics New Zealand level 
2 main categories for ethnicity (European, Māori, Pacific 
people, Asian and Middle Eastern/Latin American/
African),13 and otherwise report according to information 
provided by authors.
Where possible, we will use the International Classification 
of Diseases 11th classification (ICD-11) categories of vision 
impairment, based on presenting visual acuity in the better 
eye, that is, mild vision impairment is visual acuity of 6/12 
or worse to 6/18 inclusive; moderate vision impairment is 
visual acuity worse than 6/18 to 6/60 inclusive; severe vision 
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impairment is visual acuity worse than 6/60 to 3/60 inclusive 
and blindness is visual acuity worse than 3/60.29
We will share our synthesis of the results with the field 
experts and key stakeholders engaged during the search 
process, to get feedback on our summary of results.23
ETHICS AND DISSEMINATION
Ethical approval has not been sought as our review will 
only include published and publicly accessible data. We 
will publish the review in an open access peer- reviewed 
journal. We anticipate the findings will be useful to organ-
isations and providers in New Zealand responsible to plan 
and deliver eye care services, as well as stakeholders in 
other countries with differential access to eye care.
Collaborators N/A.
Contributors JTR drafted the protocol with suggestions from JR, JB, MH, IG and 
BW who reviewed the protocol and provided feedback on the draft. IG constructed 
the search. The final version of the protocol was approved by all authors.
Funding The authors have not declared a specific grant for this research from any 
funding agency in the public, commercial or not- for- profit sectors.
Disclaimer Award/grant number is not applicable. This research received no 
specific grant from any funding agency in the public, commercial or not- for- profit 
sectors. JTR is a recipient of the University of Auckland Senior Health Research 
Scholarship. JR’s appointment at the University of Auckland is funded by the 
Buchanan Charitable Foundation, New Zealand.
Competing interests None declared.
Patient consent for publication Not required.
Provenance and peer review Not commissioned; externally peer reviewed.
Supplemental material This content has been supplied by the author(s). It has 
not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been 
peer- reviewed. Any opinions or recommendations discussed are solely those 
of the author(s) and are not endorsed by BMJ. BMJ disclaims all liability and 
responsibility arising from any reliance placed on the content. Where the content 
includes any translated material, BMJ does not warrant the accuracy and reliability 
of the translations (including but not limited to local regulations, clinical guidelines, 
terminology, drug names and drug dosages), and is not responsible for any error 
and/or omissions arising from translation and adaptation or otherwise.
Open access This is an open access article distributed in accordance with the 
Creative Commons Attribution Non Commercial (CC BY- NC 4.0) license, which 
permits others to distribute, remix, adapt, build upon this work non- commercially, 
and license their derivative works on different terms, provided the original work is 
properly cited, appropriate credit is given, any changes made indicated, and the use 
is non- commercial. See: http:// creativecommons. org/ licenses/ by- nc/ 4. 0/.
ORCID iDs
Jaymie Tingkham Rogers http:// orcid. org/ 0000- 0003- 2415- 8198
Joanna Black http:// orcid. org/ 0000- 0002- 5100- 8796
Matire Harwood http:// orcid. org/ 0000- 0003- 1240- 5139
Ben Wilkinson http:// orcid. org/ 0000- 0002- 2629- 7063
Iris Gordon http:// orcid. org/ 0000- 0001- 8143- 8132
Jacqueline Ramke http:// orcid. org/ 0000- 0002- 5764- 1306
REFERENCES
 1 Burton MJ, Ramke J, Marques AP, et al. The Lancet global health 
Commission on global eye health: vision beyond 2020. Lancet Glob 
Health 2021;9:e489–551.
 2 Bourne R, Adelson J, Flaxman S. Trends in prevalence of blindness 
and distance and near vision impairment over 30 years and 
contribution to the global burden of disease in 2020. Lancet Glob 
Health 2020. doi:10.2139/ssrn.3582742
 3 Bourne RRA, Jonas JB, Bron AM, et al. Prevalence and causes 
of vision loss in high- income countries and in eastern and central 
Europe in 2015: magnitude, temporal trends and projections. Br J 
Ophthalmol 2018;102:575–85.
 4 Wong TY, Sabanayagam C. Strategies to tackle the global burden 
of diabetic retinopathy: from epidemiology to artificial intelligence. 
Ophthalmologica 2020;243:9–20.
 5 Yau JWY, Rogers SL, Kawasaki R, et al. Global prevalence and major 
risk factors of diabetic retinopathy. Diabetes Care 2012;35:556–64.
 6 Martin S, Siciliani L, Smith P. Socioeconomic inequalities in waiting 
times for primary care across ten OECD countries. Soc Sci Med 
2020;263:113230.
 7 Ministry of Health. Achieving equity in health outcomes: highlights 
of important national and international papers. Wellington, New 
Zealand: Ministry of Health, 2018.
 8 Taylor HR, Xie J, Fox S, et al. The prevalence and causes of vision 
loss in Indigenous Australians: the National Indigenous eye health 
survey. Med J Aust 2010;192:312–8.
 9 Gu Y, Warren J, Kennelly J, et al. Cardiovascular disease risk 
management for Māori in New Zealand general practice. J Prim 
Health Care 2014;6:286–94.
 10 Foreman J, Keel S, van Wijngaarden P, et al. Prevalence and 
causes of visual loss among the Indigenous peoples of the world: a 
systematic review. JAMA Ophthalmol 2018;136:567–80.
 11 Foreman J, Xie J, Keel S, et al. The prevalence and causes of vision 
loss in Indigenous and non- Indigenous Australians: the National eye 
health survey. Ophthalmology 2017;124:1743–52.
 12 Kelaher M, Ferdinand A, Taylor H. Access to eye health services 
among Indigenous Australians: an area level analysis. BMC 
Ophthalmol 2012;12:51.
 13 Stats NZ Tatauranga Aotearoa. Census ethnic groups dataset, 2018. 
Available: https://www. stats. govt. nz/ information- releases/ 2018- 
census- ethnic- groups- dataset [Accessed Dec 2020].
 14 Stats NZ Tatauranga Aotearoa. Census data, 2018. Available: https://
www. stats. govt. nz/ tools/ 2018- census- place- summaries/ new- 
zealand# ethnicity- culture- and- identity [Accessed Dec 2020].
 15 Atlantis E, Joshy G, Williams M. Diabetes among Māori and other 
ethnic groups in New Zealand. In: Diabetes mellitus in developing 
countries and underserved communities, 2017: 165–90.
 16 Ferdinand A, Lambert M, Trad L, et al. Indigenous engagement in 
health: lessons from Brazil, Chile, Australia and New Zealand. Int J 
Equity Health 2020;19:1–12.
 17 Sheridan NF, Kenealy TW, Connolly MJ, et al. Health equity in the 
New Zealand health care system: a national survey. Int J Equity 
Health 2011;10:45.
 18 Ellison- Loschmann L, Pearce N. Improving access to health care 
among New Zealand's Maori population. Am J Public Health 
2006;96:612–7.
 19 Kenealy T, Elley CR, Robinson E, et al. An association between 
ethnicity and cardiovascular outcomes for people with type 2 
diabetes in New Zealand. Diabet Med 2008;25:1302–8.
 20 Aljied R, Aubin M- J, Buhrmann R, et al. Prevalence and determinants 
of visual impairment in Canada: cross- sectional data from 
the Canadian longitudinal study on aging. Can J Ophthalmol 
2018;53:291–7.
 21 Yip JLY, Luben R, Hayat S, et al. Area deprivation, individual 
socioeconomic status and low vision in the EPIC- Norfolk eye study. J 
Epidemiol Community Health 2014;68:204–10.
 22 Ramke J, Jordan V, Vincent AL, et al. Diabetic eye disease and 
screening attendance by ethnicity in New Zealand: a systematic 
review. Clin Exp Ophthalmol 2019;47:937–47.
 23 Arksey H, O'Malley L. Scoping studies: towards a methodological 
framework. Int J Soc Res Methodol 2005;8:19–32.
 24 Burn H, Hamm L, Black J, et al. Eye care delivery models to improve 
access to eye care for Indigenous peoples in high- income countries: 
a scoping review. BMJ Glob Health 2021;6:e004484.
 25 Hamm LM, Black J, Burn H, et al. Interventions to promote access 
to eye care for non- Indigenous, non- dominant ethnic groups in 
high- income countries: a scoping review protocol. BMJ Open 
2020;10:e033775.
 26 Tricco AC, Lillie E, Zarin W, et al. PRISMA extension for scoping 
reviews (PRISMA- ScR): checklist and explanation. Ann Intern Med 
2018;169:467–73.
 27 Jalali S, Wohlin C. Systematic literature studies: database searches 
vs. backward snowballing. Paper presented at: International 
Symposium on Empirical Software Engineering and Measurement, 
2012.
 28 Atkinson J, Salmond C, Crampton P. NZDep2013 index of 
deprivation. Wellington: Department of Public Health, University 
of Otago, Wellington, 2014. https://www. otago. ac. nz/ wellington/ 
otago069936. pdf
 29 WHO. International classification of disease 11 vision impairment 
including blindness, 2018. Available: https:// icd. who. int/ browse11/ 
l- m/ en#/ http% 3a% 2f% 2fid. who. int% 2ficd% 2fentity% 2f30317704 
[Accessed Dec 2020].
